Previous
Next
About Us
Welcome to Satyarx
Satya is a discovery biotech, developing next-generation small-molecule oncology therapeutics that focus on unique approaches to:
- Modulate proven oncogenic drivers
- DDR Pathway/ Synthetic lethality
Satya has a world-class scientific and executive team with a successful track record of translating 75 research programs to over 15 clinical candidates across oncology and inflammatory disorders.
Leadership
Advisory Board
Leadership
Murthy Chavali
Founder and CEO
- Prior to starting Satya, CSN was CEO of Aurigene between 2005-19. During this period, Aurigene was turned around into a profitable company, and led through transformational changes to become a highly valued discovery and clinical development organization, with a pipeline of own assets and multiple partnered programs. These include small-molecule Immuno-oncology assets targeting PD-L1 and CD47, kinase inhibitor programs including FGFR, IRAK4, CDK7 and an anti-inflammatory program, targeting RoRgt. A pre-clinical pipeline of other assets including protein degraders has been developed during this time.
- Previously, CSN was COO of Gland Pharma Limited. Gland Pharma received the first FDA approval for an injectable facility in India.
- CSN started his career with ICICI Ventures, India’s first VC fund. CSN also started and led a boutique Investment Bank focused on the Life Sciences industry. He is a Chemical Engineer from IIT Madras, and an MBA from IIM, Bangalore
- He is an independent Director on the boards of Gland Pharma Limited (NSE: GLAND), Balaji Amines Limited (NSE: BALAMINES) and Vijaya Diagnostic Centre Limited.
Srikant Viswanadha, PhD
Chief Scientific Officer
Discovery to clinical development expertise across multiple projects
- Over 19 years of Pharma experience, having worked on/ led 7 projects from Discovery to Clinical Development
- MS (Idaho), PhD (Virginia Tech), Post-doc (NIH, Bethesda)
- Previously worked with Glenmark and Incozen/ Rhizen, last as Chief Scientific Officer at Rhizen
Sukanya Patra, PhD
Director, Discovery Biology
Discovery biology and target validation expertise
- Sukanya has over 16 years of research experience, including over 10 years in industry.
- Ph.D., University of California San Diego (UCSD) and San Diego State University (SDSU); M.Pharm., Jadavpur University, India
- She has participated and led multiple programs particularly focused in oncology and immune-oncology, starting from critical target evaluation, strategic differentiation, assay development, design of appropriate screening cascades, candidate identification and profiling, across many programs.
- She has been formerly Principal Scientist at Lupin, and closely involved in programs that have since reached clinical development. Along with a brilliant academic career, Sukanya has been the recipient of various awards for her outstanding contributions as a scientist through her career
Navnath Karche, PhD
Director, Medicinal Chemistry
Small Molecule discovery expertise across multiple therapeutic areas
- Over 18 years in drug discovery, with multiple programs across Oncology, Metabolic Disorders & CNS
- PhD, Pune India and Post-doc, Rouen, France
- Previously at Dai-ichi and Lupin
- Over 18 patents and 9 publications
Priyanka K
Head, Alliance Management
Over 10 years’ project and alliance management experience
- Project Manager for >25 drug discovery projects over 10 years
- Handled key IND submissions, including planning & managing activities for GMP Drug Substance, GMP Drug Product and GLP tox studies
- B Tech (Chem Engg)
Advisory Board
Ali Fattaey, Ph. D
Advisor, Science And Strategy
Seasoned Biotech Professional with >25 years in the Industry
- CEO, MetaboMed
- Seasoned Biotech professional, with over 25 years in industry including as CXO/ Founder
- VP – Research at Onyx (1994-2001), among early scientists at Onyx
- PhD, Kansas and Post-doc, Harvard
John Bondo Hansen, Ph. D
Advisor, Discovery Chemistry
Over 35 years in pharma and biotech
- Worked in drug discovery at Ferrosan, Denmark and Novo Nordisk, Denmark in positions of increasing responsibility, ending as vice president of medicinal chemistry at Novo Nordisk.
- From 2008 worked in biotech. Co-founder and member of management of several companies including Contera Pharma, which was acquired by Bukwang Pharma of Korea in 2014.
- Board member, Aurigene, India from 2008 to 2013
- Author and co-author of 77 peer-reviewed publications. Inventor or co-inventor of more than 50 published patents and patent applications.
- PhD in Medicinal chemistry from University of Copenhagen, Denmark and Post-doc, Texas A&M University, USA.
Science
Precision oncology targets to build a portfolio of assets
in DDR and oncogenic pathways
Satya is building a portfolio of therapeutics targeting
novel biological pathways including oncogenes, DDR
pathways and synthetic lethal targets.
Targets are chosen for specific patient populations
that can be uniquely addressed using bio-marker
identification strategies as well as PD markers that
can be followed both pre-clinically and in the clinic.
Pipeline
Satya’s Pipeline comprises First-In-Class and Best-In-Class Targets focused
on DDR pathway and Oncogenes.
News & Events
Satya strengthens Scientific team
Srikant Viswanadha, an accomplished industry leader, has joined Satya as its CSO. Srikant has over 19 years’ pharmaceutical experience in reputed companies,… Read More